Abstract
Radioimmunotherapy is a well-known treatment for non-Hodgkin's lymphoma. (90)yttrium (Y)-ibritumomab-tiuxetan consists of a radioisotope conjugated to a monoclonal anti-cluster of differentiation 20 antibody, which is targeted against B-lymphocytes. Initially the treatment indication was relapse of low-grade non-Hodgkin's lymphoma. However, (90)Y-ibritumomab-tiuxetan has later been used in clinical trials in the treatment of other types of non-Hodgkin's lymphoma and prior to stem cell transplantation. Based on the literature this systematic review aims to throw light on the future possibilities of radioimmunotherapy.
| Bidragets oversatte titel | Indications for radioimmunotherapy for patients with non-Hodgkin's lymphoma |
|---|---|
| Originalsprog | Dansk |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 173 |
| Udgave nummer | 20 |
| Sider (fra-til) | 1417-21 |
| Antal sider | 5 |
| ISSN | 0041-5782 |
| Status | Udgivet - 2011 |
Emneord
- Antibodies, Monoclonal
- Humans
- Lymphoma, Follicular
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Mantle-Cell
- Lymphoma, Non-Hodgkin
- Neoplasm Recurrence, Local
- Radioimmunotherapy
- Stem Cell Transplantation
- Treatment Outcome